{"id":"mitiglinide","rwe":[],"tags":[{"label":"mitiglinide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"A10BX08","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":59.721,"date":"","count":31,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 31 times (LLR=60)"},{"llr":51.605,"date":"","count":24,"signal":"Hypoglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=52)"},{"llr":50.737,"date":"","count":19,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=51)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MITIGLINIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:53:53.887286+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:54:05.211595+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MITIGLINIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:54:05.951038+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sulfonylurea receptor 1, Kir6.2 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:06.521419+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL471498/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:06.418436+00:00"}},"allNames":["mitiglinide","mitiglinide calcium","mitiglinide calcium hydrate","S 21403","KAD-1229"],"offLabel":[],"synonyms":["mitiglinide","mitiglinide calcium","mitiglinide calcium hydrate","S 21403","KAD-1229"],"timeline":[{"date":"2011-04-22","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"2011-04-22","orphan":false,"company":"","regulator":"PMDA"}],"ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"}],"modality":"Small Molecule","drugClass":"mitiglinide","explanation":"","oneSentence":"","technicalDetail":"Mitiglinide binds to the sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium channel (K_ATP), which is composed of Kir6.2 and SUR1. This binding causes a conformational change in the channel, leading to its closure and an increase in intracellular ATP levels. The increase in ATP levels inhibits the K_ATP channel, which in turn depolarizes the beta-cell membrane, opening voltage-dependent calcium channels and triggering insulin release."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1818","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MITIGLINIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MITIGLINIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:48:48.044897","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:08.300228+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"repaglinide","drugSlug":"repaglinide","fdaApproval":"1997-12-22","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nateglinide","drugSlug":"nateglinide","fdaApproval":"2000-12-22","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pramlintide","drugSlug":"pramlintide","fdaApproval":"2005-03-16","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tirzepatide","drugSlug":"tirzepatide","fdaApproval":"2022-05-13","patentExpiry":"Jun 14, 2039","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"mitiglinide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"repaglinide","brandName":"repaglinide","genericName":"repaglinide","approvalYear":"1997","relationship":"same-class"},{"drugId":"nateglinide","brandName":"nateglinide","genericName":"nateglinide","approvalYear":"2000","relationship":"same-class"},{"drugId":"pramlintide","brandName":"pramlintide","genericName":"pramlintide","approvalYear":"2005","relationship":"same-class"},{"drugId":"tirzepatide","brandName":"tirzepatide","genericName":"tirzepatide","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07444424","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-13","conditions":["Healthy Participants"],"enrollment":32,"completionDate":"2026-07-02"},{"nctId":"NCT04349696","phase":"PHASE4","title":"Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)","status":"COMPLETED","sponsor":"Orient Europharma Co., Ltd.","startDate":"2014-02-11","conditions":["Type 2 Diabetes Mellitus","Liver Dysfunction"],"enrollment":16,"completionDate":"2018-04"},{"nctId":"NCT02154347","phase":"PHASE4","title":"Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Type 2 Diabetes Mellitus"],"enrollment":178,"completionDate":""},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":585,"completionDate":"2014-05-08"},{"nctId":"NCT02143765","phase":"PHASE4","title":"Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Zhongda Hospital","startDate":"2014-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":248,"completionDate":"2015-12"},{"nctId":"NCT02503943","phase":"PHASE4","title":"Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital of Third Military Medical University","startDate":"2015-05","conditions":["Type 2 Diabetes","Overweight","Obesity","Masked Hypertension"],"enrollment":90,"completionDate":"2016-09"},{"nctId":"NCT01333592","phase":"PHASE3","title":"Long-term Study of KAD-1229 in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Type 2 Diabetes"],"enrollment":136,"completionDate":"2012-11"},{"nctId":"NCT01456130","phase":"PHASE3","title":"Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11","conditions":["Diabetes Mellitus"],"enrollment":67,"completionDate":"2013-03"},{"nctId":"NCT00663884","phase":"PHASE4","title":"Glufast On Insulin Glargine Trial in Type 2 DM","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":167,"completionDate":"2009-09"},{"nctId":"NCT01403818","phase":"PHASE1","title":"A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-06","conditions":["Healthy","Pharmacokinetics of ASP1941","Pharmacokinetics of Mitiglinide"],"enrollment":60,"completionDate":"2011-08"},{"nctId":"NCT01443221","phase":"PHASE1","title":"Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2010-12","conditions":["Healthy"],"enrollment":24,"completionDate":"2011-01"},{"nctId":"NCT01422590","phase":"PHASE1","title":"Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":26,"completionDate":"2011-04"},{"nctId":"NCT01037842","phase":"PHASE3","title":"Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2006-08","conditions":["Type 2 Diabetes"],"enrollment":145,"completionDate":"2008-05"},{"nctId":"NCT00519142","phase":"PHASE3","title":"Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Elixir Pharmaceuticals","startDate":"2007-08","conditions":["Diabetes Mellitus, Type 2"],"enrollment":367,"completionDate":"2008-10"},{"nctId":"NCT00369148","phase":"PHASE4","title":"Combination of Glinides With Premixed Insulin","status":"COMPLETED","sponsor":"Keio University","startDate":"2004-07","conditions":["Type 2 Diabets Mellitus"],"enrollment":60,"completionDate":"2006-03"},{"nctId":"NCT00566865","phase":"PHASE1","title":"Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil","status":"COMPLETED","sponsor":"Elixir Pharmaceuticals","startDate":"2007-11","conditions":["Type 2 Diabetes Mellitus"],"enrollment":14,"completionDate":"2007-12"},{"nctId":"NCT00461617","phase":"PHASE3","title":"Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2006-08","conditions":["Diabetes"],"enrollment":291,"completionDate":"2007-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"D86I0XLB13","CHEBI":"CHEBI:31740","INN_ID":"7710","UMLSCUI":"C0906166","chemblId":"CHEMBL471498","ChEMBL_ID":"CHEMBL471498","KEGG_DRUG":"D01854","DRUGBANK_ID":"DB01252","PDB_CHEM_ID":" 9I0","PUBCHEM_CID":"121891","MESH_SUPPLEMENTAL_RECORD_UI":"C087255"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":128,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BX08","allCodes":["A10BX08"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"MITIGLINIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2011-04-22T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:08.300228+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}